The Effects of Glucocorticoids on Glucose Metabolism in Patients With Interstitial Lung Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-03-31

Study Completion Date

2017-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is aimed at exploring the effects of glucocorticoids on glucose metabolism in patients with interstitial lung disease. Patients with interstitial lung disease who is on the medication of 15mg prednisolone and 7.5mg prednisolone conduct the continuous glucose monitoring (CGM). The data attained from the CGM are used to define the glycemic characteristics in patients using glucocorticoids and the difference of glucose features due to different doses.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study on COPD Corticosteroid-induced Hyperglycemia on Clinical Outcome in Patients With COPD

NCT00605007

COPD

COMPLETED

Tight Glycemic Control in Acute Exacerbations of COPD

NCT00452296

COPD Hyperglycemia

UNKNOWN NA

GLUCOSAFE 2 - A New Tool for Nutritional Management and Insulin-therapy in the Intensive Care Unit (ICU)

NCT03890432

Critical Illness Energy Supply; Deficiency, Severe Protein Deficiency +2 more

COMPLETED NA

Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 2

NCT00654797

Critically Ill Hyperglycemia

UNKNOWN PHASE2

Phase II Study of Safety and Feasibility of Intensive Blood Glucose Control With Insulin on Acute Medical Wards

NCT00764556

COPD Hyperglycemia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients diagnosed of interstitial lung disease and treating with glucocorticoids could be enrolled in this clinical trial. Those who is in an acute inflammatory phase and diagnosed with hemorrhagic disease should are excluded, so are those unwilling to carry the continuous glucose monitoring (CGM) device. When the dose of prednisolone is applied 15mg per day steadily and is going to be decreased, the CGM is conducted. At the same time, blood tests evaluating the glucose metabolism are measured, including HbA1c, GA, fasting insulin and fasting glucose. After taking 7.5mg prednisolone per day for 3 months, participants do the CGM and blood tests again to evaluate the glucose metabolism during this period. The CGM data could be used for the glucose evaluation, which can manifest the glucose characteristics in the circumstances of glucocorticoid use. By comparing the CGM data and the blood tests, the investigators hope to find the different features of the glucose metabolism due to different doses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Interstitial Lung Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

known diabetes

Participants have been diagnosed diabetes.

No interventions assigned to this group

known prediabetes

Participants have been diagnosed impaired glucose tolerance or impaired fasting glucose before.

No interventions assigned to this group

normal glucose tolerance

Participants have done the oral glucose tolerance test and been confirmed the normal glucose tolerance.

No interventions assigned to this group

unclear glucose tolerance condition

Participants who have not done oral glucose tolerance test or been diagnosed diabetes before.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with interstitial lung disease

Exclusion Criteria

* Patients who are in an acute inflammatory phase
* Patients who are diagnosed hemorrhagic disease
* Patients who are unwilling to carry the continuous glucose monitoring device

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No